LONDON (Reuters) – Europe’s medicines regulator said it was assessing evidence that GlaxoSmithKline’s successful HIV drug dolutegravir might be linked to birth defects, adding it should not be prescribed to women seeking to become pregnant.
Source: Reuters Medical News